Alert detail
FDA Approval: ENSPRYNG (SATRALIZUMAB) — Type 1 - New Molecular Entity
Policy ID: FDA-BLA761149Specialty: NeurologyAdded: 6/18/2026Effective: 2020-08-14billing update
Full alert analysis requires a subscription
Subscribe to access the complete alert summary, AI-generated action recommendations, source document links, LCD revision comparisons, and related alerts.